This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (18)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Neuro-ophthalmology  • Alert me on articles by topic

Istvan Pirko, MD; Lori K. Blauwet, MD; Timothy G. Lesnick, MSc; Brian G. Weinshenker, MD, FRCP(C)

Arch Neurol. 2004;61:1401-1405.

Background  Optic neuritis (ON) may occur in isolation or may herald multiple sclerosis (MS) or neuromyelitis optica (NMO). Occasionally, ON may recur many times without intervening evidence of dissemination in space.

Objective  To define the clinical course and prognosis of patients with recurrent ON.

Design  Retrospective medical record review and telephone follow-up survey.

Setting  Clinic-based practice in a large tertiary referral institution.

Main Outcome Measures  Survival analysis of conversion to MS and NMO and final visual impairment. We studied the association of clinical and demographic factors, the presence of brain lesions on magnetic resonance images, and the use of corticosteroid treatment at the time of the first ON occurrence with conversion to MS and NMO.

Results  We identified 1274 patients with ON between 1994 and 2000 and selected 72 (5.7%) with recurrent ON without intervening symptoms of a disseminated demyelinating condition for further analysis. The 5-year conversion rate to NMO was 12.5% and to MS, 14.4%. Among 5 patients with 2 or more lesions consistent with MS on brain magnetic resonance images, 2 (40.0%) converted to MS and none to NMO, while among 11 patients without such lesions, none converted to MS and 2 (18.2%) converted to NMO (P = .16). Conversion to MS occurred in 7 (19.4%) of 36 individuals treated for their first ON episode with corticosteroids vs 4 (44.4%) of 9 untreated individuals (P = .19). There was no difference in the conversion rate to MS between those treated with intravenous steroids (4 [16.7%] of 24) vs oral steroids (3 [25.0%] of 12) (P = .33). Conversion to NMO occurred earlier than conversion to MS (2.3 ± 1.6 vs 5.3 ± 4.3 years, respectively; P = .01). Women tended to convert to NMO more frequently than men (female-male ratio for NMO converters, 7:1; MS converters, 2:1; nonconverters, 2:1; P = .56), as did those with a higher annual frequency of ON episodes (NMO converters, 2.0 ± 1.3; MS converters, 1.0 ± 1.0; nonconverters, 0.6 ± 0.5; P = .04). The number of ON events in the first 2 years following the first ON episode was higher in the NMO group (NMO converters, 2.4 ± 0.9; MS converters, 1.9 ± 1.1; nonconverters, 1.7 ± 0.7; P = .04). The final visual impairment was greatest in the NMO group (P = .02).

Conclusions  Patients with rapid succession of severe ON events are more likely to develop a generalized demyelinating disease. Patients with NMO had a worse visual outcome.

Author Affiliations: Department of Neurology (Drs Pirko and Weinshenker), Mayo Medical School (Dr Blauwet), and Health Sciences Research, Division of Biostatistics (Dr Lesnick), Mayo Clinic, Rochester, Minn.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

NMO-IgG predicts the outcome of recurrent optic neuritis
Matiello et al.
Neurology 2008;70:2197-2200.
ABSTRACT | FULL TEXT  

Clinical Course of Optic Neuritis in Patients With Relapsing Neuromyelitis Optica
Papais-Alvarenga et al.
Arch Ophthalmol 2008;126:12-16.
ABSTRACT | FULL TEXT  

Differential diagnosis and evaluation in pediatric multiple sclerosis
Hahn et al.
Neurology 2007;68:S13-S22.
ABSTRACT | FULL TEXT  

Clinical profile of simultaneous bilateral optic neuritis in adults
de la Cruz and Kupersmith
Br. J. Ophthalmol. 2006;90:551-554.
ABSTRACT | FULL TEXT